MCID: END057
MIFTS: 76

Endometrial Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 53 12 49 71 36 13 51 14
Endometrial Carcinoma 12 28 13 51 14 69
Malignant Neoplasm of Endometrium 12 69
Carcinoma, Endometrioid 41 69
Endometrial Neoplasms 41 69
Endometrial Neoplasm 12 28
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 53
Endometrial Carcinoma, Somatic 53
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 53
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Endometrioid Carcinoma 12
Uterine Corpus Cancer 69
Tumor of Endometrium 12
Endometrial Ca 12
Endmc 71

Classifications:



Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot : 71 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and small cell carcinoma, and has symptoms including endometrial carcinoma An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and ERK Signaling. The drugs Estradiol and Megestrol acetate have been mentioned in the context of this disorder. Affiliated tissues include tissues lining the uterus, uterus and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A uterine cancer that is located in tissues lining the uterus.

Wikipedia : 72 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

Description from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 32.8 CCND1 CDKN2A CTNNB1 KRAS MLH1 MLH3
2 small cell carcinoma 31.8 EGFR PTEN TP53
3 adenocarcinoma 31.5 CCND1 CDH1 CDKN2A CTNNB1 EGF EGFR
4 breast cancer 31.1 CCND1 CDH1 CTNNB1 EGF EGFR ERBB2
5 mucinous adenocarcinoma 31.1 CDKN2A EGFR KRAS MLH1 TP53
6 uterine carcinosarcoma 31.0 CTNNB1 EGFR ERBB2 ESR2 PGR PIK3CA
7 ovarian cancer 31.0 CCND1 CDH1 CTNNB1 EGF EGFR ERBB2
8 endometrial adenocarcinoma 31.0 CDKN2A CTNNB1 EGFR ERBB2 ESR1 ESR2
9 hereditary breast ovarian cancer syndrome 30.9 MLH1 MSH2 MSH6 PTEN TP53
10 transitional cell carcinoma 30.9 CDH1 EGFR ERBB2 MSH2 TP53
11 atypical polypoid adenomyoma 30.9 CTNNB1 MLH1 MSH2
12 cervical carcinosarcoma 30.9 ESR1 PGR TP53
13 leiomyoma, uterine 30.8 EGF ESR1 ESR2 PGR
14 pancreatic cancer 30.8 CCND1 CDH1 CDKN2A CTNNB1 EGF EGFR
15 adenosquamous carcinoma 30.8 EGFR KRAS TP53
16 colorectal cancer 30.7 CCND1 CDH1 CDKN2A CTNNB1 EGF EGFR
17 melanoma 30.7 CCND1 CDH1 CDKN2A CTNNB1 PTEN TP53
18 uterine corpus endometrial carcinoma 12.1
19 endometrial adenosquamous carcinoma 11.1
20 high-grade neuroendocrine carcinoma of the corpus uteri 11.1
21 sebaceous adenoma 11.0 EGF ESR1 MLH1 MSH2 MSH6
22 mismatch repair cancer syndrome 11.0 CTNNB1 MLH1 MSH2 MSH6 PTEN
23 small intestine cancer 11.0 CCND1 KRAS MLH1 MSH2 MSH6
24 synchronous bilateral breast carcinoma 11.0 CCND1 ESR1 PGR PTEN TP53
25 inflammatory breast carcinoma 11.0 CDH1 EGFR ERBB2 ESR1 PGR
26 breast metaplastic carcinoma 11.0 CDH1 EGFR ERBB2 ESR1 PGR TP53
27 colorectal adenocarcinoma 11.0 CDH1 CTNNB1 EGFR KRAS MLH1 MSH2
28 cecum adenocarcinoma 11.0 KRAS MLH1 MSH2 MSH6
29 lipid-rich carcinoma 11.0 CDH1 EGFR ERBB2 ESR1 PGR
30 mixed cell type cancer 11.0 ERBB2 ESR1 KRAS PGR TP53
31 appendix carcinoid tumor 11.0 MLH1 MSH2 MSH6
32 tumor suppressor gene on chromosome 11 11.0 EGFR ERBB2 KRAS PIK3CA PTEN
33 adenosquamous colon carcinoma 11.0 MLH1 MSH2 MSH6
34 tubular adenocarcinoma 11.0 CDH1 EGFR ERBB2 ESR1 PGR
35 breast scirrhous carcinoma 11.0 EGFR ERBB2 ESR1 PGR
36 female reproductive endometrioid cancer 11.0 CTNNB1 PGR PTEN TP53
37 hidradenocarcinoma 11.0 CCND1 EGFR ERBB2 ESR1 TP53
38 oncocytic breast carcinoma 11.0 EGFR ERBB2 ESR1 PGR
39 breast squamous cell carcinoma 11.0 CDH1 EGFR ERBB2 PGR
40 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.0 CTNNB1 KRAS PIK3CA PTEN TP53
41 breast adenoid cystic carcinoma 11.0 EGFR ERBB2 ESR1 PGR
42 vestibular gland benign neoplasm 11.0 ESR1 PGR TP53
43 malignant ovarian surface epithelial-stromal neoplasm 11.0 CDH1 ERBB2 KRAS PGR PIK3CA TP53
44 ovary epithelial cancer 11.0 CDH1 ERBB2 KRAS PGR PIK3CA TP53
45 ductal carcinoma in situ 11.0 CCND1 CDH1 EGFR ERBB2 ESR1 PGR
46 bartholin's gland adenoma 11.0 ESR1 PGR TP53
47 breast benign neoplasm 11.0 ERBB2 ESR1 PGR TP53
48 thoracic benign neoplasm 11.0 ERBB2 ESR1 PGR TP53
49 glassy cell carcinoma of the cervix 11.0 ERBB2 ESR1 PGR
50 uterine corpus cancer 11.0 ERBB2 ESR1 PGR TP53

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Clinical features from OMIM:

608089

Human phenotypes related to Endometrial Cancer:

31
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 31 HP:0012114

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

25 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.68 KRAS PIK3CA EGFR
2 Decreased viability GR00106-A-0 10.68 KRAS
3 Decreased viability GR00221-A-1 10.68 PIK3CA CDH1 KRAS CDKN2A EGFR ESR1
4 Decreased viability GR00221-A-2 10.68 KRAS PIK3CA ESR1
5 Decreased viability GR00221-A-3 10.68 CDKN2A ERBB2
6 Decreased viability GR00221-A-4 10.68 PIK3CA CDKN2A EGFR ESR1 ERBB2
7 Decreased viability GR00301-A 10.68 KRAS CDH1 MLH3 MSH2
8 Decreased viability GR00381-A-1 10.68 KRAS
9 Decreased viability in esophageal squamous lineage GR00235-A 10.03 ERBB2 ESR1 KRAS MLH1 PGR PIK3CA
10 Increased cell death HMECs cells GR00103-A-0 9.63 CTNNB1 EGFR PGR PIK3CA PTEN TP53
11 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.35 CCND1 ESR1 ESR2 MSH2 PTEN
12 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.17 MLH1 MLH3 MSH2 MSH3 MSH6 MUTYH

MGI Mouse Phenotypes related to Endometrial Cancer:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.56 MSH2 MSH3 MSH6 MUTYH PGR PIK3CA
2 homeostasis/metabolism MP:0005376 10.51 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
3 endocrine/exocrine gland MP:0005379 10.49 CCND1 CDH1 CDKN2A CTNNB1 EGF EGFR
4 integument MP:0010771 10.49 CCND1 CDH1 CDKN2A CTNNB1 EGF EGFR
5 digestive/alimentary MP:0005381 10.47 MLH1 MSH2 MSH3 PTEN TP53 CCND1
6 mortality/aging MP:0010768 10.45 TP53 CCND1 CDH1 CDKN2A CTNNB1 EGFR
7 cardiovascular system MP:0005385 10.42 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
8 neoplasm MP:0002006 10.41 CCND1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
9 growth/size/body region MP:0005378 10.39 PTEN TP53 ESR2 KRAS PIK3CA CCND1
10 immune system MP:0005387 10.39 CCND1 CDH1 CDKN2A CTNNB1 EGF EGFR
11 behavior/neurological MP:0005386 10.36 ESR1 ESR2 KRAS PGR PIK3CA PTEN
12 embryo MP:0005380 10.33 CDKN2A CTNNB1 EGFR CDH1 ERBB2 ESR1
13 hematopoietic system MP:0005397 10.31 CCND1 CDKN2A CTNNB1 EGFR ESR1 ESR2
14 nervous system MP:0003631 10.25 CCND1 CDKN2A CTNNB1 EGFR ERBB2 ESR1
15 muscle MP:0005369 10.22 CDKN2A CTNNB1 EGFR ERBB2 ESR1 ESR2
16 limbs/digits/tail MP:0005371 10.18 CTNNB1 EGFR ERBB2 ESR1 ESR2 KRAS
17 reproductive system MP:0005389 10.16 CCND1 CDH1 CDKN2A CTNNB1 EGF PIK3CA
18 normal MP:0002873 10.15 ERBB2 ESR1 ESR2 KRAS CCND1 CDH1
19 liver/biliary system MP:0005370 10.11 CDKN2A CTNNB1 EGFR ESR1 ESR2 KRAS
20 no phenotypic analysis MP:0003012 10.1 CDH1 CDKN2A CTNNB1 EGFR ESR1 ESR2
21 respiratory system MP:0005388 9.9 CCND1 CDKN2A CTNNB1 EGFR ERBB2 ESR1
22 pigmentation MP:0001186 9.8 CDKN2A CTNNB1 EGFR KRAS PTEN TP53
23 skeleton MP:0005390 9.73 PGR PIK3CA PTEN TP53 CCND1 CDKN2A
24 vision/eye MP:0005391 9.32 TP53 CCND1 CDKN2A CTNNB1 EGF EGFR

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
2
Megestrol acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 595-33-5 11683
3
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
4
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 4091 14219
5
Peppermint Approved, Nutraceutical Phase 4
6
Megestrol Phase 4,Phase 2,Phase 3,Phase 1 3562-63-8 3080587 19090
7
Medroxyprogesterone Phase 4,Phase 3,Phase 2 520-85-4 10631
8 Estradiol valerate Phase 4,Phase 2 979-32-8
9 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1
10 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Contraceptive Agents, Male Phase 4,Phase 3,Phase 2
12 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Estradiol 17 beta-cypionate Phase 4,Phase 2
17 Estradiol 3-benzoate Phase 4,Phase 2
18 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
19 Polyestradiol phosphate Phase 4,Phase 2
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
21 Appetite Stimulants Phase 4,Phase 2,Phase 3,Phase 1
22 taxane Phase 4,Phase 1
23 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
24 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
27
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
28
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
29
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 38904 498142
30
Levonorgestrel Approved, Investigational Phase 3,Phase 2 797-63-7, 17489-40-6 13109
31
Letrozole Approved, Investigational Phase 3,Phase 2 112809-51-5 3902
32
Menthol Approved Phase 3 2216-51-5 16666
33
Methylene blue Approved, Investigational Phase 3 61-73-4
34
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
35
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
36
Ifosfamide Approved Phase 3 3778-73-2 3690
37
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
38
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
40
Epirubicin Approved Phase 3 56420-45-2 41867
41
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
42
Bazedoxifene Approved, Investigational Phase 3 198481-32-2
43
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
44
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
46
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
47
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
48
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
49
Genistein Investigational Phase 3,Phase 1 446-72-0 5280961
50
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703

Interventional clinical trials:

(show top 50) (show all 676)

# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
4 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
7 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Not yet recruiting NCT03423082 Phase 4 18F fluciclovine
8 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4 transdermal Megace
9 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
10 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
11 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
12 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
13 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
14 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
15 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
16 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
17 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
18 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
19 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
20 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
21 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
22 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
23 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
24 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
25 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
26 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
27 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
28 Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Completed NCT00490087 Phase 3
29 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
30 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
31 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
32 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
33 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
34 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
35 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
36 Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00670319 Phase 3 Raloxifene HCL;Raloxifene HCL;Placebo
37 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Recruiting NCT02762214 Phase 3
38 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
39 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
40 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
41 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Recruiting NCT02598219 Phase 3 Pre-operative SN mapping with Nanocis;Intra-operative SN mapping with patent V blue dye;Intra-operative SN mapping with indocyanin green
42 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Recruiting NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
43 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
44 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
45 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
46 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
47 Laparoscopic Approach to Cancer of the Endometrium Active, not recruiting NCT00096408 Phase 3
48 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin
49 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
50 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 28 CDH1 MLH3 MSH3 MSH6 PTEN
2 Endometrial Neoplasm 28

Anatomical Context for Endometrial Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

18
Tissues Lining The Uterus

MalaCards organs/tissues related to Endometrial Cancer:

38
Uterus, Lymph Node, Testes, Endothelial, Lung, Colon, Liver

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 1560)
# Title Authors Year
1
Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. ( 29439179 )
2018
2
Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. ( 29417286 )
2018
3
Correction to: SEOM clinical guidelines for endometrial cancer (2017). ( 29417438 )
2018
4
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer. ( 29444159 )
2018
5
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. ( 29449189 )
2018
6
Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. ( 29434922 )
2018
7
Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway. ( 29449346 )
2018
8
PGK1 and GRP78 overexpression correlates with clinical significance and poor prognosis in Chinese endometrial cancer patients. ( 29416645 )
2018
9
Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae. ( 29445866 )
2018
10
Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. ( 29416671 )
2018
11
Folate receptor-I+ targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. ( 29416655 )
2018
12
Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. ( 29426961 )
2018
13
Skeletal Muscle Quality Beyond Average Muscle Attenuation: A Proposal of Skeletal Muscle Phenotypes to Predict Short-Term Survival in Patients With Endometrial Cancer. ( 29439176 )
2018
14
Chest wall metastasis of endometrial cancer: case report and review of the literature. ( 29433406 )
2018
15
Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis. ( 29441458 )
2018
16
Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies? ( 29426745 )
2018
17
Differential expression of ten-eleven translocation genes in endometrial cancers. ( 28349832 )
2017
18
Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. ( 28947174 )
2017
19
Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. ( 28061006 )
2017
20
The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer. ( 28303356 )
2017
21
Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. ( 28526167 )
2017
22
Current strategies in the diagnosis of endometrial cancer. ( 28508342 )
2017
23
Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer. ( 28533799 )
2017
24
Clinical characteristics of Lynch-like cases collaterally classified by Lynch syndrome identification strategy using universal screening in endometrial cancer. ( 28847642 )
2017
25
Detection of recurrence in early stage endometrial cancer - the role of symptoms and routine follow-up. ( 28080157 )
2017
26
InA vivo MR spectroscopy predicts high tumor grade in endometrial cancer. ( 28927296 )
2017
27
ATF4 regulates CCL2 expression to promote endometrial cancer growth by controlling macrophage infiltration. ( 28843961 )
2017
28
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. ( 28532857 )
2017
29
Costs of Robotic-Assisted Versus Traditional Laparoscopy in Endometrial Cancer. ( 28937446 )
2017
30
Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. ( 28067948 )
2017
31
Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System. ( 28062022 )
2017
32
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. ( 28945226 )
2017
33
Prognostic Impact of ABO Blood Group on Type I Endometrial Cancer Patients- Results from Our Own and Other Studies. ( 28928872 )
2017
34
The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment. ( 29059634 )
2017
35
Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. ( 28938695 )
2017
36
Obesity and Endometrial Cancer: A Lack of Knowledge but Opportunity for Intervention. ( 28937804 )
2017
37
The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells. ( 28177128 )
2017
38
Triple negative endometrial cancer. ( 28509323 )
2017
39
Case Report of Menopausal Woman Diagnosed with Endometrial Cancer after Colon Cancer with Germline Mutation in MSH6 in Korea. ( 28523262 )
2017
40
Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. ( 27582547 )
2017
41
Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer. ( 28820751 )
2017
42
Primum non nocere: Are we ready for POLE testing in endometrial cancer? ( 28947175 )
2017
43
High mRNA levels of 17I^-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. ( 27923582 )
2017
44
RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer. ( 28528974 )
2017
45
Prevalence and prognostic role of mismatch repair gene defect in endometrial cancer patients. ( 28946809 )
2017
46
Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer. ( 28083737 )
2017
47
Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer. ( 28668893 )
2017
48
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. ( 28709704 )
2017
49
Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis. ( 28669560 )
2017
50
Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. ( 28401338 )
2017

Variations for Endometrial Cancer

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

71
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

ClinVar genetic disease variations for Endometrial Cancer:

6 (show all 13)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh38 Chromosome 5, 80675103: 80675103
2 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
3 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh37 Chromosome 12, 25398279: 25398279
4 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
5 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913478 GRCh37 Chromosome 10, 123274794: 123274794
6 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh37 Chromosome 10, 123274803: 123274803
7 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
8 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh37 Chromosome 2, 48027853: 48027853
9 MSH6 NM_000179.2(MSH6): c.10C> T (p.Gln4Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786201042 GRCh37 Chromosome 2, 48010382: 48010382
10 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
11 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
12 MLH3 MLH3, 1-BP DEL, 885G deletion Pathogenic
13 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh37 Chromosome 10, 89690847: 89690847

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 741)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM6444840 XPO1 endometrium,NS,carcinoma,endometrioid carcinoma c.1658G>A p.R553H 15
2 COSM286575 XPO1 endometrium,NS,carcinoma,endometrioid carcinoma c.2246G>A p.R749Q 15
3 COSM46074 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.604C>T p.R202C 15
4 COSM6932 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.733G>A p.G245S 15
5 COSM10660 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.818G>A p.R273H 15
6 COSM10648 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.524G>A p.R175H 15
7 COSM10808 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.488A>G p.Y163C 15
8 COSM43708 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.422G>A p.C141Y 15
9 COSM11582 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.395A>G p.K132R 15
10 COSM43906 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.843C>A p.D281E 15
11 COSM11066 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.578A>T p.H193L 15
12 COSM10663 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.916C>T p.R306* 15
13 COSM11183 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.799C>T p.R267W 15
14 COSM10768 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.535C>T p.H179Y 15
15 COSM43767 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.406C>G p.Q136E 15
16 COSM43837 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.843C>G p.D281E 15
17 COSM43753 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.560-1G>A p.? 15
18 COSM10704 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.844C>T p.R282W 15
19 COSM10662 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.743G>A p.R248Q 15
20 COSM11483 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.848G>A p.R283H 15
21 COSM303910 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.691A>C p.T231P 15
22 COSM10656 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.742C>T p.R248W 15
23 COSM43765 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.727A>C p.M243L 15
24 COSM10709 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.722C>G p.S241C 15
25 COSM10705 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.586C>T p.R196* 15
26 COSM44130 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.477C>T p.A159A 15
27 COSM10659 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.817C>T p.R273C 15
28 COSM3970361 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.472C>A p.R158S 15
29 COSM10690 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.473G>A p.R158H 15
30 COSM43766 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.899C>T p.P300L 15
31 COSM10722 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.853G>A p.E285K 15
32 COSM43632 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.493C>T p.Q165* 15
33 COSM43663 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.826G>C p.A276P 15
34 COSM10889 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.536A>G p.H179R 15
35 COSM10788 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.764T>G p.I255S 15
36 COSM96339 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.993G>T p.Q331H 15
37 COSM43684 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.720T>G p.S240R 15
38 COSM11196 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.734G>T p.G245V 15
39 COSM10735 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.638G>A p.R213Q 15
40 COSM45268 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.827C>A p.A276D 15
41 COSM11305 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.809T>C p.F270S 15
42 COSM10742 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.578A>G p.H193R 15
43 COSM10654 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.637C>T p.R213* 15
44 COSM10779 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.818G>T p.R273L 15
45 COSM10731 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.707A>G p.Y236C 15
46 COSM10810 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.725G>T p.C242F 15
47 COSM43714 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.836G>A p.G279E 15
48 COSM11090 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.541C>T p.R181C 15
49 COSM43768 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.700T>G p.Y234D 15
50 COSM6444838 TGFBR2 endometrium,NS,carcinoma,endometrioid carcinoma c.159T>G p.F53L 15

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27